Summit Therapeutics shares fell about 16% on Monday after the U.S. Food and Drug Administration turned down its application for the lung cancer drug ivonescimab. The stock traded at $11.82 at 2:20 p.m. Eastern time, down $2.33, or 16.5%, from Friday’s close of $14.15.
Summit said on Sunday that the FDA had issued a complete response letter, meaning the application cannot be approved in its present form. The drug, given with chemotherapy, was meant for patients with advanced non-small cell lung cancer who had already been treated with EGFR-targeted drugs. In the HARMONi trial it significantly delayed the cancer’s progression, but the FDA said that without a statistically significant improvement in overall survival, the benefit did not support approval.
“We are disappointed for patients and their families awaiting additional treatment options in this setting,” Chairman and Co-Chief Executive Robert Duggan said. Summit said it will keep developing ivonescimab in other uses, including first-line lung cancer and colorectal cancer.
Monday’s price was below the stock’s lowest close of the past year, $12.43 on Aug. 20. The shares had already fallen 21% over the four trading days before the decision, from $17.84 on Nov. 9.
…
That’s the story. … Thank you for listening to Cedar Global Markets. We’re supported by our partners, and you can learn more about the partner featured on this page. We’ll see you next time.




